Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apalolithovolrelimab
- Development stage
- Phase 2
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Apalolithovolrelimab (eparlitozoviril) is an experimental dual immune checkpoint inhibitor designed to simultaneously target programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). It is currently being investigated in a Phase II clinical trial as an adjuvant therapy for patients with resectable hepatocellular carcinoma (HCC) who exhibit microvascular invasion (MVI), a high-risk factor for postoperative recurrence. By blocking both PD-1 and CTLA-4 pathways, the drug aims to restore and enhance the anti-tumor activity of T cells, potentially reducing the risk of recurrence and improving long-term survival in HCC patients following surgical resection. The drug is administered via intravenous infusion at a dose of 7.5 mg/kg every three weeks.
- Other names
- eparlitozovirilapalolithovolrelimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on apalolithovolrelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apalolithovolrelimab.